Clinical Trials Logo

Hurler's Syndrome clinical trials

View clinical trials related to Hurler's Syndrome.

Filter by:
  • None
  • Page 1

NCT ID: NCT00668564 Terminated - Clinical trials for Niemann-Pick Disease, Type C

Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism

Start date: March 2008
Phase: Phase 2
Study type: Interventional

The primary objective of this clinical trial is to evaluate the ability to achieve and sustain donor engraftment in patients with lysosomal and peroxisomal inborn errors of metabolism undergoing hematopoietic stem cell transplantation (HCT).

NCT ID: NCT00418821 Terminated - Clinical trials for Mucopolysaccharidosis I

A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants

Start date: October 22, 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine if laronidase is present in the breast milk of post-partum women receiving Aldurazyme® (laronidase) and the effects of Aldurazyme (laronidase) on the growth, development, and immunologic response of their breastfed infants.

NCT ID: NCT00146770 Completed - Clinical trials for Mucopolysaccharidosis I

Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients

Start date: May 2001
Phase: Phase 3
Study type: Interventional

This study is being conducted to collect additional long-term efficacy and safety data of Aldurazyme® (laronidase) patients with MPS I disease. Patients who were previously enrolled in the Phase 3 Double-Blind Study will be enrolled in this study.

NCT ID: NCT00144781 Completed - Clinical trials for Mucopolysaccharidosis I

A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease

Start date: December 2004
Phase: Phase 4
Study type: Interventional

The main purpose of this study is to evaluate differences in the pharmacodynamic response of 4 Aldurazyme® (laronidase) dose regimens in patients with Mucopolysaccharidosis I (MPS I).

NCT ID: NCT00144768 Completed - Clinical trials for Mucopolysaccharidosis I

A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients

Start date: July 2004
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether the development of antibodies to laronidase in patients with MPS I receiving Aldurazyme® impairs the clearance of GAG substrate.